Mallinckrodt plc is presented as the former parent of two companies that became separate after a 2025 merger and subsequent spin-off. Par Health develops generics, sterile injectables, and active pharmaceutical ingredients, while Keenova Therapeutics focuses on specialty therapeutics for patients with rare, stigmatized, or unaddressed conditions. The homepage identifies Par Health and Keenova as separate companies with their own missions and identities.